**Author details**

and the optimal transformation of preclinical success into experimental design. The genetic and proteomic technologies show great potential to detect the novel biomarkers in cancer research. We place great expectations on these technologies to

This work was supported by the Chengdu Medical College Natural Science Foundation (CYZ18-08, CYZ18-20, CYZ18-33), the Sichuan Provincial Education Department (17ZA0134), the Sichuan Medical Association (S18023), and Sichuan undergraduate innovation and startup program funding support (S201913705080,

XF developed the general idea and drafted the manuscript with CJ; YLQ and DYX searched the reference, HK sort the clinical trials data, PTT and ZS participated in drafting process and double check the data; LFF drew the figure; GM

personalize treatment for advanced pancreatic cancer patients.

proofread the manuscript and ensure the general quality.

The authors declare that they have no competing interests.

All data will be made available upon reasonable request.

**Acknowledgements**

*Current Cancer Treatment*

S201913705130, S201913705059).

**Authors' contribution**

**Competing interests**

**Ethics statement**

Not applicable.

Not applicable.

**138**

**Consent for publication**

**Availability of data and material**

Jie Chen1,2†, Liqiong Yang3†, Yuxi Duan3†, Tinging Pu3 , Sha Zheng<sup>3</sup> , Fangfang Liu<sup>4</sup> , Kun Huang<sup>5</sup> , Greg Mirt6 and Fan Xu<sup>7</sup> \*

1 School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

2 Department of Orthopedics, Shanghai Institute of Traumatology and Orthopedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China


© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
